News Releases

Select year
Categories

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

May 27, 2026 | Products | Corporate

Read more

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

May 26, 2026 | Products

Read more

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

May 15, 2026 | Products

Read more

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Apr 30, 2026 | Products

Read more

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

Apr 16, 2026 | Products

Read more

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

Apr 14, 2026 | Products

Read more

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Apr 09, 2026 | Products

Read more

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer 

Mar 17, 2026 | Products

Read more

Myriad Commercially Launches Precise MRD with Select Community Oncologists

Mar 02, 2026 | Products

Read more

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Feb 24, 2026 | Products

Read more

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 19, 2026 | Products

Read more

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Jan 27, 2026 | Products

Read more